Company profile
Celentyx | Immunology CRO | Immuno-oncology Fibrosis Neuroinflammation
Immunology CRO: immuno-oncology, autoimmunity, inflammation, fibrosis and neuroinflammation assays using healthy donor or patient tissues and cells
Financial period: 1 Jan 2024 to 31 Dec 2024
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
Last confirmation statement made up date
Last accounts made up date
AA | Transaction MzQzNzU2MjA0NGFkaXF6a2N4
Published 27 Sep 2024 04:21
Company registered at Companies House
1 Jan 2021 to 30 Jun 2022
The urgency of the current COVID-19 pandemic needs new treatments to be developed as quickly and as safely as possible. Whatever comes out of the many labs involved in these efforts needs to be tested in a variety of ways to help us know if they will work when given to people who might be infected by SARS-CoV-2, the virus which causes COVID-19\. For the v...
